ArticleCost effectiveness and resource allocation : C/E2026
Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma.
I-Ting Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.